These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7706173)

  • 1. Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study.
    Stobberingh EE; Maclaren DM; Schmitz PI
    J Antimicrob Chemother; 1994 Nov; 34(5):777-83. PubMed ID: 7706173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
    Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
    J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Karlowsky JA; Weaver MK; Thornsberry C; Dowzicky MJ; Jones ME; Sahm DF
    J Clin Microbiol; 2003 Jul; 41(7):3339-43. PubMed ID: 12843088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
    Livermore DM; Mushtaq S; James D; Potz N; Walker RA; Charlett A; Warburton F; Johnson AP; Warner M; Henwood CJ
    Int J Antimicrob Agents; 2003 Jul; 22(1):14-27. PubMed ID: 12842324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
    Baron EJ; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):141-51. PubMed ID: 7648835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
    Liebowitz LD; Klugman KP
    S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
    Marshall SA; Aldridge KE; Allen SD; Fuchs PC; Gerlach EH; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):153-68. PubMed ID: 7648836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam].
    García-Rodríguez JA; Trujillano I;
    Rev Esp Quimioter; 2002 Jun; 15(2):169-75. PubMed ID: 12582446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
    Gould IM; Milne K
    J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals.
    Verbist L; Dhoore P
    Acta Clin Belg; 1995; 50(5):274-81. PubMed ID: 8533527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
    Mokaddas E; Rotimi VO; Sanyal SC
    J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
    Grimm H
    Eur J Surg Suppl; 1994; (573):25-9. PubMed ID: 7524792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.
    Collins LA; Wennersten CB; Ferraro MJ; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1994 Jan; 38(1):144-6. PubMed ID: 8141570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
    Reeves DS; Holt HA; Bywater MJ; MacGowan AP
    J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
    Appelbaum PC; Spangler SK; Jacobs MR
    J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.